From lost in translation to paradise found: Enabling protein biomarker method transfer by mass spectrometry

Clinical Chemistry

Volumn 60, Issue 7, 2014, Pages 941-944

  Grant, Russell P ^a,c   Hoofnagle, Andrew N ^b  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN PROCESSING; PROTEOMICS; TANDEM MASS SPECTROMETRY;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; PROTEINS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84903700861     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.224840     Document Type: Article

References (16)

1. Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature 2012;483:531-3.
2. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
3. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008;2:1386-402.
4. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11.
5. Kushnir MM, Rockwood AL, Roberts WL, Abraham D, Hoofnagle AN, Meikle AW. Measurement of thyroglobulin by liquid chromatographytandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies. Clin Chem 2013;59:982-90.
6. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014;13:907-17.
7. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-28.
8. DeSilva B, Garofolo F, Rocci M, Martinez S, Dumont I, Landry F, et al. 2012 white paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis 2012;4:2213-26.
9. U. S. Food and Drug Administration. Guidance for industry: bioanalytical method validation. http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf (Accessed February 18, 2014).
10. Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic experiments. J Proteome Res 2009;8:2144-56.
11. Miller WG, Myers GL, Lou Gantzer M, Kahn SE, Schonbrunner ER, Thienpont LM, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011;57:1108-17.
12. Ichihara K, Boyd JC, Intervals ICoR, Decision L. An appraisal of statistical procedures used in derivation of reference intervals. Clin Chem Lab Med 2010;48:1537-51.
13. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein a-i and apolipoprotein b by liquid-chromatography- multiplereactionmonitoring mass spectrometry. Clin Chem 2010;56:1804-13.
14. Cox HD, Lopes F, Woldemariam GA, Becker JO, Parkin MC, Thomas A, et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin Chem 2014;60:541-8.
15. Kushnir MM, Rockwood AL, Nelson GJ, Yue B, Urry FM. Assessing analytical specificity in quantitative analysis using tandem mass spectrometry. Clin Biochem 2005;38:319-27.
16. Abbatiello SE, Mani DR, Keshishian H, Carr SA. Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem 2010;56:291-305.